Stock Quote        
  Join        Login  
logo

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Generic Drug Makers Benefit From Expiring Rights and Expanding Medicaid Coverage

Wednesday, March 30, 2011 9:27 AM

NEW YORK, NY -- (Marketwire) -- 03/30/11 -- www.shinesroomonline.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at www.shinesroomonline.com to have free access to this research and speak to one of our pros.

Generic drug makers may be better positioned for growth than their name brand counterparts with the amount of companies facing expiring exclusivity rights. An expanding, budget minded Medicaid program could also help generate revenues for generic drug makers. Visit www.shinesroomonline.com to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

www.shinesroomonline.com is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at www.shinesroomonline.com. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Mylan Pharmaceuticals is among generic drug makers benefitting from expiring exclusivity deals. The company expects to launch 500 products globally this year, some of which carry limited competition clauses and a few with 180 days of exclusivity. Mylan Inc. report is accessible for free by registering today at http://shinesroomonline.com/reports/March3011MylanInc.(MYL)300311.php.

Rising Medicaid costs in 2010 may compel some states to adjust rules to encourage more generic prescriptions. Considering that another 16 million people could be added to the Medicaid program by 2019, emphasizing generic drugs may be necessary to keep the cost of the program down.

The only clear negative factors working against companies within the industry at the moment are legal battles. Watson Pharmaceuticals Inc. is currently being sued by Purdue Pharmaceuticals for allegedly violating a number patents. Watson Pharmaceuticals Inc. report is accessible for free by registering today at http://shinesroomonline.com/reports/March3011WatsonPharmaceuticalsInc.(WPI)300311.php.

The two Drugs - Generic stocks research reports are available for free by signing up now on www.shinesroomonline.com.

About Shinesroomonline.com

Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesroomonline.com/policy.php?disclaimer=true.

Contact Person:
Michael Thomas Smith
Marketing Coordinator
info@shinesroomonline.com


(Source: Market Wire )
(Source: Quotemedia)

Follow iStockAnalyst on Twitter Follow iStockAnalyst on Twitter
Subscribe to Email Alerts
Advertisement

Comments Closed





Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.